Sulfadimethoxine Tablets

This product is a long-acting sulfonamide drug. It has antibacterial effects on non-enzyme-producing Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Salmonella, Shigella and other Enterobacteriaceae, Neisseria gonorrhoeae, Neisseria meningitidis, and Haemophilus influenzae. Sulfonamide drugs are broad-spectrum antibacterial agents. Its mechanism of action is that it is similar to para-aminobenzoic acid (PABA) in structure and can compete with PABA on dihydrofolate synthase in bacteria, thereby preventing PABA from synthesizing folic acid required by bacteria as a raw material and reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purines, thymine nucleotides and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria.

The chemical name is: N-(6-methoxy-4-pyrimidinyl)-4-aminobenzenesulfonamide. Its structural formula is: Molecular formula: C11H12N4O3S Molecular weight: 280.31

This product is white or slightly yellow tablets.

This product is suitable for urinary tract infections, intestinal infections and skin and soft tissue infections caused by sensitive bacteria.

Oral administration for adults: 1g for the first dose, 0.5g each time thereafter, once a day; for children over 2 months old, 15mg/kg per day, double the first dose.

1. Allergic reactions are relatively common and may manifest as drug rashes. In severe cases, exudative erythema multiforme, exfoliative dermatitis, and epidermolysis bullosa atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity reactions, drug fever, joint and muscle pain, and fever. 2. Neutropenia or deficiency, thrombocytopenia, and aplastic anemia. Patients may experience sore throat, fever, pallor, and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. This is more likely to occur in patients with glucose-6-phosphate dehydrogenase (G-6PD) deficiency after the use of sulfonamides, and is more common in newborns and children than in adults. 4. Hyperbilirubinemia and neonatal kernicterus. Because sulfonamides compete with bilirubin for protein binding sites, free bilirubin can increase. Newborns have imperfect liver function, so they are more likely to occur.

1. Patients who are allergic to sulfonamides are contraindicated. 2. Because this product blocks the metabolism of folic acid and aggravates the folate deficiency in patients with megaloblastic anemia, patients with this disease

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. Urine alkalinizing drugs can enhance the solubility of this product in alkaline urine and increase excretion. 2. It cannot be used in combination with PABA, because PABA can replace this product to be taken up by bacteria, and the two are antagonistic to each other. 3. When the following drugs are used together with this product, this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action or toxicity. Therefore, when these drugs are used at the same time as this product, or when used after the application of this product, their dosages need to be adjusted. Such drugs include oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium. 4. When used in combination with bone marrow suppressive drugs, the adverse reactions of such drugs to the hematopoietic system may be enhanced. If there is an indication to use two types of drugs together, possible toxic reactions should be closely observed. 5. Long-term use with contraceptives (estrogens) can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When used in combination with thrombolytic drugs, their potential toxic effects may be increased. 7. When used in combination with hepatotoxic drugs, the incidence of hepatotoxicity may increase. Liver function should be monitored for such patients, especially those who have been taking the drug for a long time and have a history of liver disease. 8 Additive photosensitivity may occur when used in combination with photosensitizing drugs. 9 Patients receiving this product have an increased need for vitamin K. 10 It should not be used in combination with methenamine, because methenamine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with this product, increasing the risk of crystalluria. 11 This product can replace the plasma protein binding site of phenylbutazone, and when the two are used together, the effect of phenylbutazone can be enhanced. 12 When sulfinpyrazone is used in combination with this product, it can reduce the latter's secretion from the renal tubules, resulting in increased and persistent blood drug concentrations, thereby producing toxicity. Therefore, the dose of this product may need to be adjusted during or after the use of sulfinpyrazone. When the course of sulfinpyrazone treatment is long, the blood concentration of sulfonamides should be monitored to help adjust the dose and ensure safe medication.

Keep away from light and store in sealed container.

0.5g

24 months

Henan Life Pharmaceutical Co., Ltd.

• Founded in:

  2008-02-22

• Address:

  Room 803, Nanyang Zhongguancun Information Valley Innovation Center, Jianhe Road, Nanyang High-tech Zone, Nanyang City, Henan Province

• Tax NO.:

  9141130074070920XE

• Registered Funds:

  17.25 million yuan

• Email:

  Log in to view